Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Malignant Melanoma Treatment Market $8.5 Billion by 2031

The global market for malignant melanoma treatment estimated to reach $8.5 billion by 2031, growing at a CAGR of 4.7% over the forecast period, driven by continued uptake of new drugs, with several promising molecules in the active development.

  • Other factors driving the market growth include high unmet needs, increasing melanoma incidence leading to large patient pool, coupled with an anticipated increase in branded therapy prescription, launch of premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations.
Global Malignant Melanoma Treatment Market

There are two main types of skin cancer: melanoma and non-melanoma. Melanoma is a malignant neoplasm of melanocytes, the pigment cells within the epidermis. 95% of melanomas develop in the skin and is a significant source of morbidity and mortality worldwide.

  • According to World Cancer Research Fund (WCRF), melanoma of the skin is the 19th most commonly occurring cancer in men and women. There were nearly 300,000 new cases in 2018.
  • As per the WHO statistics, the incidence of melanoma skin cancers has been increasing over the past decades. Currently, 132,000 melanoma skin cancers occur globally each year.
  • According to Skin Cancer Foundation statistics, more than 9,500 people are diagnosed with skin cancer every day in the U.S. In 2017, approximately 87,110 individuals are predicted to be diagnosed with melanoma in the United States alone.

The five world regions with the greatest melanoma incidence were Australasia, North America, Eastern Europe, Western Europe and Central Europe. Internationally, incidence varies worldwide. White populations in Australia, New Zealand, South Africa, and the southern United States have the highest rates, while Asian populations in Hong Kong, Singapore, China, India, and Japan have the lowest rates.

  • The risk of melanoma increases with age, although more recently, the number of new cases in the younger population (ages ≤40 years) has been on the rise. The growing cost of melanoma continues to highlight the medical need to find cost-effective means of prevention and reduce the economic burden of malignant melanoma.

Although the primary cutaneous melanoma can be managed by surgery, the advanced metastatic melanoma cannot be managed by surgery alone and thus, requires better therapeutic approaches. In recent years, better understanding of melanoma biology, as well as cancer and immune biology in general has led to the development of a number of new potential therapeutic agents for advanced melanoma.

  • Standard therapy with for unresectable malignant melanoma with cytotoxic therapy agents such as dacarbazine, temozolomide and IL-2 is associated with notoriously lower response rates.
    • Until recently, patients with metastatic melanoma were treated with chemotherapy such as DTIC and cytokines such as interleukin-2 (IL-2). There are a number of chemotherapy agents employed in the treatment of melanoma, e.g. dacarbazine (DTIC), temozolomide, paclitaxel, cisplatin, and carboplatin.
  • The metastatic or unresectable disease can be treated with immunotherapy, or with targeted therapy.
    • For immunotherapy, PD-1 inhibitor monotherapy with pembrolizumab or nivolumab, or the combination of nivolumab and ipilimumab is recommended, whereas for targeted therapy, combination therapy with dabrafenib/trametinib or vemurafenib/cobimetinib is recommended.
      • The first immunotherapy and targeted therapy agents to improve survival were Bristol-Myers Squibb’s Yervoy (ipilimumab) and Roche’s Zelboraf (vemurafenib), respectively. There is much optimism that the PD-1 inhibitors and new combinations of agents are likely to yield even greater improvements.

The global malignant melanoma therapeutics market research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for malignant melanoma treatment segmented by drug class (product/brand) – cytotoxic therapy agents [Dacarbazine (imidazole carboxamide), Temodar (temozolomide)], cytokines and viral vector vaccines [interleukin-2 – Proleukin (aldesleukin), interferons – Intron A (Interferon alfa-2b) and Sylatron (Peginterferon alfa-2b), T‑Vec / Imlygic (talimogene laherparepvec)], BRAF inhibitors [Braftovi (encorafenib), Zelboraf (vemurafenib), Tafinlar (dabrafenib)], MEK inhibitors [Mektovi (binimetinib), Mekinist (trametinib), Cotellic (cobimetinib)], immune checkpoint inhibitors – PD-1/PD-L1 inhibitors [Keytruda (pembrolizumab), Opdivo (nivolumab), Tecentriq (atezolizumab)], CTLA-4 inhibitors [Yervoy (ipilimumab)], and geography.

  • Based on the drug classes, the immune checkpoint inhibitors segment accounted for the largest share of total malignant melanoma market, and also anticipated to grow at the fastest rate during the forecast period.
    • The melanoma market has been changed dramatically by the advent of immuno-oncology (IO) therapies, the PD-1 inhibitors, Bristol-Myers Squibb Co.’s Yervoy (ipilimumab) and Opdivo (nivolumab), and Merck & Co. Inc.’s Keytruda (pembrolizumab).
      • Despite strong competition, Bristol-Myers Squibb to remain the leader of the checkpoint immunotherapy and overall melanoma market. Yervoy has rapidly become the best-selling brand in melanoma, approaching blockbuster status in 2013, with growth fuelled by recent label extension in the first-line setting in Europe.
        • However, competition in this drug class is becoming intense as Merck’s Keytruda (pembrolizumab), which was approved in the US in 2014, is also expected to obtain first-line approval and garner uptake across the major markets.
  • The targeted treatment melanoma market is currently dominated by Novartis AG’s MEK inhibitor Mekinist (trametinib) and BRAF inhibitor Tafinlar (dabrafenib), which are approved alone and in combination with each other and Roche’s MEK/BRAF combination of Zelboraf and Cotellic (cobimetinib).
    • The BRAF/MEK inhibitor combination therapies are expected to garner label expansion in the adjuvant setting for high-risk early-stage resected patients.
      • With approval from the European Commission secured for the combination of its BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib), Pierre Fabre Group is now focusing on access for its metastatic melanoma therapy in a crowded market.
  • Although stimulation of the immune system holds great promise for cancer treatment, many challenges remain, including a limited response rate and even resistance in some patients.
    • At the same time, the patients may suffer from severe immune-related adverse events (irAEs), resulting from an overactivated immune response. Both the variable clinical response and irAEs demand predictive models to support patient management.

The global malignant melanoma treatment market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

  • Geographically, the North America region dominated the total market followed by the Europe region, and continue its dominance during the forecast period, in part due to increasing incidence of melanoma skin cancer, premium-priced drugs and favorable reimbursement policies.
    • However, sales in the Asia Pacific and Latin America regions are expected to increase by the end of the forecast period, due to high unmet needs, coupled with increasing cost-consciousness to limit the premium pricing opportunities for pipeline agents in the developing regions.     

In addition, the global market research report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for malignant melanoma therapeutics and profiled in this report include Amgen, Inc. (BioVex, Inc.), Array BioPharma, Inc., Bristol-Myers Squibb Company, Clinigen Group, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pierre Fabre Group, Pfizer, Inc., and Roche Holding AG (Chugai Pharmaceutical Co. Ltd.).

  • Drug Class (Product/Brand)
    • Cytotoxic Therapy Agents
      • Dacarbazine (imidazole carboxamide, DTIC)
      • Temodar / Temodal / Temcad (temozolomide, TMZ)
    • Cytokines and Viral Vector Vaccines
      • Interleukin-2 (IL-2) – Proleukin (aldesleukin)
      • Interferons (IFNs) – Intron A (Interferon alfa-2b) and Sylatron (Peginterferon alfa-2b)
      • T‑Vec / Imlygic (talimogene laherparepvec)
    • BRAF (B-Raf proto-oncogene, serine/threonine kinase) Inhibitors
      • Braftovi (encorafenib)
      • Zelboraf (vemurafenib)
      • Tafinlar (dabrafenib)
    • Mitogen and Extracellular-regulated protein Kinase (MEK) Inhibitors
      • Mektovi (binimetinib)
      • Mekinist (trametinib)
      • Cotellic (cobimetinib)
    • Immune Checkpoint Inhibitors
      • Programmed Cell Death 1 receptor/Programmed Cell Death Ligand 1 (PD-1/PD-L1) Inhibitors
        • Keytruda (pembrolizumab)
        • Opdivo (nivolumab)
        • Tecentriq (atezolizumab)
      • Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA-4) Inhibitors
        • Yervoy (ipilimumab)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Amgen, Inc. (BioVex, Inc.)
    • Array BioPharma, Inc.
    • Bristol-Myers Squibb Company
    • Clinigen Group
    • Merck & Co., Inc.
    • Novartis AG
    • Pierre Fabre Group
    • Pfizer, Inc.
    • Roche Holding AG (Chugai Pharmaceutical Co. Ltd.)

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com